Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SLV337 suspension
SLV337 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | PLACEBO_COMPARATOR | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| 4 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo |
| SLV337 | DRUG | SLV337 400 mg/day |
Inclusion Criteria Type 2 diabetes ,stable dose of Metformin,HbA1c \>= 7%, but \< 9% Exclusion Criteria Type 1 diabetes mellitus, Body Mass Index (BMI) \>40.0 kg/m2, evidence of unstable cardiovascular diseases, NYHA class I to IV, ALT \> 1.5 times UNL, creatinine clearance \<60 mL/min
Top 16 of 30 competitors
SLV337 is an investigational small molecule developed by Abbott Laboratories for the treatment of Type 2 Diabetes. It is a suspension formulation and has been studied in a Phase 2 clinical trial. SLV337 is not approved and remains in clinical development.
SLV337 was studied as a treatment for adults with Type 2 Diabetes. The Phase 2 trial enrolled 61 patients aged 18 years and older across Bulgaria, Poland, and South Africa. SLV337 is investigational and has not been approved for any use.
SLV337 is developed by Abbott Laboratories, which trades on the New York Stock Exchange under the ticker ABT. Abbott conducted the clinical development of the compound, including the completed Phase 2 study in patients with Type 2 Diabetes.
SLV337 is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The study was a randomized, double-blind, placebo-controlled safety and pharmacokinetic/pharmacodynamic study in patients with Type 2 Diabetes.
SLV337 has been evaluated in one completed Phase 2 trial, NCT00924534, titled A Safety PK/PD Study of SLV337 in Patients With Type 2 Diabetes. The randomized, double-blind, placebo-controlled study enrolled 61 patients across Bulgaria, Poland, and South Africa.
Yes, SLV337 suspension is another name for SLV337. Both refer to the same investigational small molecule developed by Abbott Laboratories for Type 2 Diabetes, and searches for either name point to the same Phase 2 compound.